Phase I accelerated dose-escalation study to determine the safety and tolerability of CYT997 when given as an oral capsule every two weeks in patients with advanced solid tumours.
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Lexibulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors YM BioSciences Australia
- 25 Feb 2009 Status changed from recruiting to completed, as reported in the Australian New Zealand Clinical Trials Registry.
- 26 May 2008 The expected completion date for this trial is now 1 Oct 2008.
- 19 Dec 2007 New trial record.